Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
Sponsored by Gilead Sciences
About this study
The goal of this observational study is to generate real-life information on the use of lenacapavir (LEN, YEZTUGO®, (YTG)) for pre-exposure prophylaxis (PrEP) across diverse clinical settings in the United States. The study will characterize how PrEP is initiated, used, and discontinued in routine clinical practice when LEN is added as PrEP option and will evaluate persistence on LEN PrEP. The primary objective of this study is to evaluate real-life persistence on LEN PrEP at Week 52 in diverse clinical settings in the United States.
Where this study is enrolling (7)
- I'm interested
Grady Memorial Hospital
Atlanta, Georgia
- Call 773.388.1600
Howard Brown Health
Chicago, Illinois
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- I'm interested
Rush University Medical Center/Division of Infectious Diseases
Chicago, Illinois
- I'm interested
DOM/Project WISH Research Clinic
Chicago, Illinois
- Call (312) 864-0200
Ruth M. Rothstein CORE Center
Chicago, Illinois
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
Show all 7 locations
- Call 713-873-4000
Thomas Street at Quentin Mease Health Center
Houston, Texas
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- I'm interested
UT Health
Houston, Texas
Who can participate
Inclusion criteria
- ✓Able to comprehend and provide a signed written informed consent, which must be obtained prior to initiation of screening study procedures;
- ✓Willing and able to comply with all study requirements;
- ✓Presents at a study site needing or wanting PrEP for HIV prevention as determined by local clinical practice guidelines and institutional protocols, including new PrEP users (PrEP naïve) and current or former users of oral (emtricitabine/tenofovir disoproxil fumarate (coformulated; Truvada®; F/TDF) or emtricitabine/tenofovir alafenamide (coformulated; Descovy®; F/TAF)) or injectable (LEN or cabotegravir (CAB)) PrEP who indicate interest in discussing PrEP methods that they are clinically eligible to receive;
- ✓Eligible for LEN PrEP per standard of care procedures, for example, being HIV-1 negative at screening using a Food and Drug Administration (FDA) approved/cleared test for diagnosis of acute or primary HIV-1 infection;
- ✓After PrEP counseling to learn about the advantages and disadvantages of various PrEP methods:
- ✓1. Selects LEN PrEP as their chosen PrEP method; OR,
- ✓2. Selects a different PrEP method or chooses not to start or continue PrEP.
Exclusion criteria
- ✕Any other indication not already listed above that would make the participant ineligible for LEN PrEP at enrollment according to local guidelines, organizational protocols, US Prescribing Information (USPI) for the PrEP product, and/or Center for Disease and Control (CDC) guidance.
- ✕Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.